Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.00    2.00 (3.23%)
Bid:
63.00
Ask:
65.00
Spread: 2.00 (3.175%)
Market Cap: £15.59m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Broker Option

21 Mar 2022 17:56

RNS Number : 5151F
MyCelx Technologies Corporation
21 March 2022
 

THIS ANNOUNCEMENT, (INCLUDING THE APPENDICES) AND THE TERMS AND CONDITIONS SET OUT HEREIN (TOGETHER, THIS "ANNOUNCEMENT") AND THE INFORMATION CONTAINED THEREIN, IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE, DISTRIBUTION OR FORWARDING, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO ANY US PERSONS OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OF SECURITIES IN ANY JURISDICTION. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

 

21 March 2022

MYCELX Technologies Corporation

("MYCELX" or the "Company")

Broker Option

 

 

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, is pleased to announce that further to the announcement of the Proposed Placing and Subscription on 11 March 2022, the Broker Option has been exercised in respect of 155,000 new Common Shares (the "Broker Option Shares"), raising additional gross proceeds of $101,500 (c £77,500) for the Company.

The Broker Option Shares will be issued at a price of 50 pence per new Common Share (being the Issue Price) and on the same terms and conditions as the Placing, including the fact that they are to be issued into the new restricted line of Common Shares under the symbol MYXR. 

With the exercise of the Broker Option and the admission of the Placing and Subscription to trading on AIM, this results in a total gross fundraise of $2.31million (c.£1.77 million*) for the Company; comprising the Placing and Subscription raising c.$2.21 million (c.£1.69 million*) (before expenses), and the Broker Option raising $101,500 (c.£77,500*).

Admission and dealings

Application will be made to the London Stock Exchange for the 155,000 Broker Option Shares to be admitted to trading on AIM (the "Further Admission"). Admission of the Placing and Subscription became effective on 21 March 2022, the Broker Option Shares are expected to become effective and dealings commence at 8.00 a.m. on or around 25 March 2022.

The new Common Shares to be issued in connection with the Placing and Subscription and the Broker Option, when issued, rank pari passu with the existing Common Shares, including the right to receive future dividends.

Upon the Further Admission, the new Common Shares issued pursuant to the Broker Option will also trade in the Company's new restricted line of Common Shares under the symbol MYXR, and the new Common Shares, as represented by depositary interests ("Depository Interests"), will be held in the CREST system and will be segregated into a separate trading system within CREST identified with the marker "REG S" and USU624551235.

Total Voting Rights

Following the Further Admission, and as a result of the Broker Option being partially exercised, the total number of Common Shares in the Company with voting rights is expected to be 22,983,023.

Terms and definitions used in this announcement shall have the same meaning as ascribed to them in the Company's announcements dated 11 March 2022 regarding the Proposed Placing and Subscription unless otherwise stated.

 

*Exchange rate of GBP: USD 1.31

further information, please contact:

 

MYCELX Technologies Corporation

 

Connie Mixon, Chief Executive Officer

 

+1 770 534 3118

Kim Slayton, Chief Financial Officer

 

 

Canaccord Genuity Limited (NOMAD, Broker and Bookrunner)

Henry Fitzgerald-O'Connor

Gordon Hamilton

Sam Lucas (ECM)

+44 207 523 8000

 

 

Celicourt Communications (Financial PR)

 

Mark Antelme

+44 208 434 2643

Jimmy Lea

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FURUASBRUWUOUAR
Date   Source Headline
3rd Jun 20267:00 amRNSAppointment of Non-Executive Director
12th May 20267:00 amRNSNew Gulf of Mexico Lease Award with Super Major
7th May 20267:00 amRNSFinal Results for the Year Ending 31 December 2025
16th Feb 202610:46 amRNSDirector Dealing
20th Jan 20267:00 amRNSTrading Update
22nd Dec 202511:27 amRNSHolding(s) in Company
7th Nov 20252:51 pmRNSHolding(s) in Company
3rd Nov 20257:00 amRNSTrading Update & $3.9m Project Award
1st Oct 20257:00 amRNSHolding(s) in Company
23rd Sep 20255:00 pmRNSResult of Annual Meeting
23rd Sep 20257:00 amRNSAppointment of New Chairman and Succession
17th Sep 20257:00 amRNSHalf Year Results Statement
11th Sep 20257:00 amRNSClosure of Restricted Stock Line
22nd Aug 20257:00 amRNSMailing of Notice of 2025 Annual Meeting
20th Aug 20257:00 amRNSOpening of $500,000 Line of Credit
17th Jul 20257:00 amRNSTrading Update
10th Jun 20257:00 amRNSMailing of 2024 Annual Report
21st May 20253:25 pmRNSDirector Dealing
19th May 202511:33 amRNSHolding(s) in Company
15th May 202511:21 amRNSHolding(s) in Company
12th May 20257:00 amRNSFinal Results for the Year Ending 31 December 2024
6th May 20257:00 amRNSPFAS Contract Award
1st May 20257:00 amRNS-REPA Announces Actions to Combat PFAS Contamination
10th Apr 20257:00 amRNSGrant of Share Options
7th Apr 20257:00 amRNSOperational and Trading Update
30th Jan 20257:00 amRNSChange of Adviser
6th Jan 20257:00 amRNSYear-end Update
29th Oct 20247:00 amRNSProject Award
24th Sep 20247:00 amRNSHalf Year Results Statement
23rd Sep 20247:00 amRNSTrading Update
6th Sep 202411:54 amRNSHolding(s) in Company
5th Sep 20245:17 pmRNSHolding(s) in Company
30th Aug 20247:00 amRNSBroker Option
23rd Aug 202411:05 amRNSDirector Dealings & Total Voting Rights
23rd Aug 20247:00 amRNSProposed Placing and Subscription
19th Jul 202410:36 amRNSPFAS Update
9th Jul 20242:23 pmRNSResult of AGM
9th Jul 20241:39 pmRNSHolding(s) in Company
4th Jun 20247:00 amRNS2023 Annual Report & Notice of 2024 Annual Meeting
21st May 20247:00 amRNSDirector Dealing
16th May 20247:00 amRNSFinal Results for the Year Ending 31 December 2023
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.